Ceftobiprole

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Antimicrobial Agent

Conditions

Antimicrobial Agent, Cephalosporins, Drug Resistance

Trial Timeline

Apr 1, 2009 → Jun 1, 2009

NCT ID

NCT00965042

About Ceftobiprole

Ceftobiprole is a phase 1 stage product being developed by Basilea Pharmaceutica for Antimicrobial Agent. The current trial status is completed. This product is registered under clinical trial identifier NCT00965042. Target conditions include Antimicrobial Agent, Cephalosporins, Drug Resistance.

What happened to similar drugs?

1 of 1 similar drugs in Antimicrobial Agent were approved

Approved (1) Terminated (1) Active (0)

✅daptomycin 6 mg/kg IVMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00965042	Phase 1	Completed	Apr 1, 2009	Jun 1, 2009	Antimicrobial Agent
NCT00771524	Phase 1	Completed	Apr 1, 2009	Feb 1, 2010	Total Hip Replacement Surgery
NCT00771719	Phase 1	Terminated	Oct 1, 2008	Nov 1, 2009	Ventilator Associated Pneumonia
NCT01026740	Phase 1	Completed	Jun 1, 2007	Sep 1, 2007	Staphylococcal Skin Infections

Competing Products

1 competing product in Antimicrobial Agent

See all competitors

Product	Company	Stage	Hype Score
daptomycin 6 mg/kg IV	Merck	Approved	35